SGI-7079

Overview

SGI-7079 is a selective, ATP-competitive, orally active inhibitor of the receptor tyrosine kinase Axl . SGI-7079 blocks Axl-mediated signaling pathways such as NF-κB activation and MMP-9 expression, thereby inhibiting tumor cell proliferation, migration and invasion. SGI-7079 is mainly used in the research of malignant tumors such as inflammatory breast cancer and bladder cancer , as well as in combination with immunization (used in combination with PD-1 therapy)[1][2][3].

Application

Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > TAM Receptor

Product Information

• Catalog No.: HY-12964
• CAS No.: 1239875-86-5
• Molecular Formula: C26H26FN7
• Molecular Weight: 455.53
• Purity: 99.32%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.17 mg/mL (4.76 mM); Clear solution
• Availability: In-stock

Source

Original product source